S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
NASDAQ:ESPR

Esperion Therapeutics Social Media Sentiment

$5.25
-3.72 (-41.47%)
(As of 12/3/2021 04:00 PM ET)
Add
Compare
Today's Range
$4.96
$6.10
50-Day Range
$5.25
$12.62
52-Week Range
$4.96
$39.49
Volume
28.74 million shs
Average Volume
1.70 million shs
Market Capitalization
$152.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.91

Reddit Posts Over Time

wallstreetbets Posts Over Time

Media Mentions Over Time



View Trending Media Stocks

MarketBeat New Follows Over Time



View Trending Stocks on MarketBeat

MarketBeat Searches Over Time



Google Searches Over Time


Social Media Mentions

Recent Reddit Threads

September 23rd, 2021  10:40 AM  |  bitternessoflife |  StockMarket
$ESPR - Utilization rate, short interest and more - partially DD

I have made small DD about $ESPR on other subs - those who want to check it out you will find posts in my profile. I am not saying this is any close to being accurate as I am still learning the stock market. I wanted to ask question about utilization. Right now, Ortex is showing …

September 22nd, 2021  6:46 AM  |  bitternessoflife |  smallstreetbets
$ESPR - here is why this will be on the rise for days to come - DD

A brief analysis of why Esperion Therapeutics (ESPR:NASDAQ) will move higher. First of all, I must admit that that the earnings, EPS are not great at all but I would not be posting this here if it was about ESPR being a value stock - because it probably is not. According …

September 11th, 2021  3:25 PM  |  AliasAvon |  WallStreetbetsELITE
Is $ESPR The Next Big Short Squeeze? Most likely 🧐 Infact all conditions are met except one Which is The Volume That Rivals The Free Float.

$ESPR is a Pharmaceutical Company that missed their sales/revenue throughout 2020 only netting around 1.5 million in sales dropping it from its 52week high of $40.20 to its 52 week low on Friday of $11.48 well last quarter they hit over 17 million in sales thats a huge turnaround …

September 9th, 2021  3:11 PM  |  Romano_Soprano |  wallstreetbets
ESPR - Esperion Therapeutics

Can someone check the fresh data shorts on #ESPR. It looks like the company is heavily shorted but has a good potential to grow. Right now its at the bottom. ​

This page was last updated on 12/5/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.